{"product_id":"legn-bcg-matrix","title":"(LEGN) Legend Biotech Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Legend Biotech Corporation BCG Matrix is a strategic analysis tool that helps you assess the company’s products or business units across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual report content, so you can review the format and insight before buying. Purchase the full version to get the complete ready-to-use analysis instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI 1 approved franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARVYKTI, Legend Biotech Corporation's only marketed product, is a BCMA-directed CAR-T for relapsed or refractory multiple myeloma and the company's clear growth engine. In fiscal 2025, it remained the dominant revenue driver, with Legend Biotech Corporation reporting product revenue above $1 billion. As the only approved franchise, it sits in the Stars bucket: high growth, high share, and still the core value creator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple myeloma label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARVYKTI moved into earlier multiple myeloma settings, which expands Legend Biotech Corporation’s addressable pool and keeps this as a Stars business. In 2024, Johnson \u0026amp; Johnson reported CARVYKTI sales of $1.2 billion, up 93% year over year, showing strong early-line demand. The move from late-line to earlier use is a classic high-growth driver, with more eligible patients and deeper penetration ahead.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCMA target leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBCMA remains one of the most validated targets in multiple myeloma, with 2 approved CAR-T therapies and a still-expanding treatment pool. Legend Biotech Corporation’s strongest share is here through CARVYKTI, which keeps winning use in a market that is still early in penetration. The target is a clear Star: high growth, strong clinical proof, and leading franchise momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJanssen global commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech’s partnership with Janssen Biotech is a clear Star because CARVYKTI gets global scale fast: Janssen co-develops and co-commercializes it across the U.S. and ex-U.S. markets, which matters in CAR-T where launch costs are high and utilization must rise fast. In 2025, CARVYKTI stayed Legend Biotech’s main revenue driver and remained the only approved BCMA CAR-T for multiple myeloma. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJanssen expands market reach.\u003c\/li\u003e\n\u003cli\u003eScale improves CAR-T economics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s CAR-T scale-up depends on tightly controlled cell-therapy manufacturing and cold-chain logistics, so added capacity can cut turnaround time and lift output. That matters because CARVYKTI already operates in a high-demand, high-complexity market, and each new slot or site still burns cash before volume catches up. In BCG terms, this is the “Stars” trade-off: growth first, margin later.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore capacity means faster patient supply.\u003c\/li\u003e\n\u003cli\u003eSpecialized logistics protect product quality.\u003c\/li\u003e\n\u003cli\u003eScale-up raises cash burn before payback.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI Tops $1B as Legend Biotech’s Growth Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCARVYKTI is Legend Biotech Corporation’s Star: 2025 product revenue topped $1 billion, and it remains the company’s only marketed product. Expansion into earlier multiple myeloma lines should keep demand high, while the Janssen partnership supports global reach. High growth is clear, but scale-up still weighs on cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStars driver\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARVYKTI revenue\u003c\/td\u003e\n\u003ctd\u003eAbove $1B in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ\u0026amp;J 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$1.2B, up 93%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLegend Biotech BCG Matrix: stars, cash cows, question marks, and dogs mapped for investment, hold, or divest signals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLegend Biotech BCG Matrix: clear quadrant view that pinpoints pain points fast for smarter portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise source trail for Legend Biotech, boosting credibility and helping decision-makers verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI commercial sales base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARVYKTI is Legend Biotech Corporation’s only recurring revenue engine, and it already sells in relapsed\/refractory multiple myeloma, an approved setting with repeat demand. The franchise delivered about $1.4 billion in 2024 global sales, so it is the closest thing to a cash cow in Legend Biotech Corporation’s BCG mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanssen profit-share economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJanssen profit-share economics turn CARVYKTI sales into recurring cash for Legend Biotech Corporation, with Janssen covering a large share of development and commercialization spend. J\u0026amp;J reported CARVYKTI sales of $963 million in 2024, up 91% year over year, which helps Legend scale cash flow as the franchise matures. That shared-cost model lowers Legend's funding burden and supports cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement-backed demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCAR-T for multiple myeloma is now part of standard care in major markets, with the U.S. expected to see about 36,110 new multiple myeloma cases in 2025. Reimbursement and growing center familiarity lower access friction, which supports steadier CARVYKTI demand. As uptake matures, higher-throughput treatment can lift margin quality over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstalled treatment-center network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s installed treatment-center network fits a cash-cow profile because CAR-T delivery only works through authorized centers with trained teams, so once a site is live, each extra patient adds less new cost. CARVYKTI sales rose to $963 million in 2024, showing how a built-out center base can keep scaling volume without the same level of new infrastructure spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAuthorized centers create a fixed, reusable delivery base.\u003c\/li\u003e\n\u003cli\u003eTraining costs are front-loaded, then spread over volume.\u003c\/li\u003e\n\u003cli\u003eIncremental infusions are cheaper to serve.\u003c\/li\u003e\n\u003cli\u003eHigher volume can lift cash generation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSingle-franchise revenue concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation has no second approved product, so one franchise carries the business. FY2024 revenue was about $1.0 billion, driven almost entirely by CARVYKTI sales, which helps fund R\u0026amp;D and scale-up. That makes the base concentrated, but CARVYKTI’s growing demand can still act like a cash cow if uptake stays strong.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle approved franchise\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue about $1.0 billion\u003c\/li\u003e\n\u003cli\u003eFunds operations and R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eDurable, but concentrated cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARVYKTI Powers Legend Biotech’s $1.4B Cash Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCARVYKTI is Legend Biotech Corporation’s only clear cash cow, with 2024 global sales of about $1.4 billion and Johnson \u0026amp; Johnson reporting $963 million, up 91% year over year. Its profit-share model and authorized-center network make revenue repeatable and keep serving costs lower as volume grows. With no second approved product, cash flow stays concentrated, but CARVYKTI still anchors funding for R\u0026amp;D and expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 global sales\u003c\/td\u003e\n\u003ctd\u003e$1.4 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ\u0026amp;J reported sales\u003c\/td\u003e\n\u003ctd\u003e$963 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e91%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved revenue driver\u003c\/td\u003e\n\u003ctd\u003eCARVYKTI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eLegend Biotech Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Legend Biotech Corporation BCG Matrix you’ll receive after purchase. No demo pages, no watermarks—just the complete, ready-to-use report. Once purchased, the same document is instantly available for download and practical use. It’s a clean, professional file built for strategic review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreclinical solid-tumor programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s preclinical solid-tumor programs are Dogs: they have no human efficacy data yet, while solid tumors make up about 90% of adult cancers and remain one of the hardest cell-therapy settings. With no clinical proof and no disclosed revenue contribution, these assets have low share and high technical risk versus CARVYKTI’s commercial focus in hematologic cancer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreclinical infectious-disease programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s preclinical infectious-disease programs are still early and non-commercial, so they sit squarely in the Dogs bucket. There is no disclosed product revenue or market share tied to these assets, and the near-term return profile is weak. Until at least one program reaches clinical proof and a clear path to filing, capital tied here has low current payback.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo second marketed therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeyond CARVYKTI, Legend Biotech has no other approved product, so most of its pipeline still lacks commercial pull. In FY2024, CARVYKTI drove nearly all revenue, with product sales of about $1.0 billion, showing heavy dependence on one asset. That kind of narrow base fits the \"dog\" label in BCG terms: low market breadth, weak diversification, and limited near-term cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core exploratory discovery work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation still runs small cell-therapy discovery bets outside its core myeloma franchise. These programs are early-stage and usually generate little or no revenue, so they burn cash before they can prove value. That fits dog behavior in a BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage, high-burn work\u003c\/li\u003e\n\u003cli\u003eOutside core myeloma focus\u003c\/li\u003e\n\u003cli\u003eLow payoff visibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWith 2025 revenue still driven mainly by CARVYKTI, these exploratory projects look non-core and hard to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo late-stage breadth outside MM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of FY2025, Legend Biotech Corporation still leans on 1 commercial asset, Carvykti, while the disclosed pipeline remains mostly Phase 1\/2 and preclinical. With no late-stage non-multiple myeloma program to seed a second revenue engine soon, the maturity gap is clear. Weak breadth and weak share outside MM keep this in \"dogs\" territory.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 commercial asset; no near-term second base\u003c\/li\u003e\n\u003cli\u003ePipeline is still early-stage heavy\u003c\/li\u003e\n\u003cli\u003eNo late-stage depth outside MM\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech’s Early Bets Burn Cash, Not Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s Dogs are the early, non-commercial bets outside CARVYKTI: they have no disclosed revenue, no human efficacy proof, and weak near-term cash return. In FY2025, CARVYKTI still carried the business, with revenue near $1.0B, so these assets remain low-share, high-burn, and far from a second growth engine.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset class\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical solid-tumor programs\u003c\/td\u003e\n\u003ctd\u003eNo human data\u003c\/td\u003e\n\u003ctd\u003eLow share, high risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfectious-disease programs\u003c\/td\u003e\n\u003ctd\u003eNo disclosed revenue\u003c\/td\u003e\n\u003ctd\u003eNon-core, weak payback\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther early pipeline\u003c\/td\u003e\n\u003ctd\u003eNo late-stage depth\u003c\/td\u003e\n\u003ctd\u003eCash burn before proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCD20 CAR-T for NHL\/DLBCL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCD20 CAR-T for NHL\/DLBCL sits in a large, growing market: diffuse large B-cell lymphoma makes up about 30% of non-Hodgkin lymphoma cases, and the U.S. sees roughly 80,000 new NHL cases a year. But the field is crowded, with several approved CAR-Ts already in market, so Legend Biotech Corporation’s share is still low. That makes this more of a high-potential question mark than a clear star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCD22 CAR-T for ALL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCD22 CAR-T for acute lymphoblastic leukemia is a real growth option, but it is still early-stage. In relapsed\/refractory ALL, CD22 is a clear target, and small trials have reported deep responses in heavily pretreated patients, but durability and safety are not yet proven at scale. That keeps this program in the Question Mark box for Legend Biotech Corporation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCD19 CAR-T for B-cell malignancies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCD19 is a proven B-cell target with real scale: the U.S. now has multiple approved CD19 CAR-Ts, and the space keeps growing in relapsed\/refractory lymphoma and leukemia. But it is also crowded, so Legend Biotech Corporation would need clearly better durability, safety, or access data to win share. Without a sharp edge, this stays a high-potential but hard-to-defend Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhase I gastric cancer candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s phase I gastric cancer candidate is still first-in-human, so it remains a Question Mark in the BCG Matrix. Gastric cancer is a large unmet-need market, with about 1.0 million new cases and 660,000 deaths worldwide each year, but share cannot be assigned until early safety and efficacy data read out. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst-in-human stage.\u003c\/li\u003e\n\u003cli\u003eBig unmet-need market.\u003c\/li\u003e\n\u003cli\u003eEarly data will set share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhase I T-cell lymphoma candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s Phase I T-cell lymphoma candidate is still an early bet, so it fits the Question Marks bucket. T-cell lymphoma is a small market, but it is clinically tough and has limited good options.\u003c\/p\u003e\n\u003cp\u003eIf early data show clear response and manageable safety, this asset could move into a niche growth story. The key test is whether its Phase I signals can justify later-stage spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage, high-risk asset\u003c\/li\u003e\n\u003cli\u003eSmall but hard-to-treat market\u003c\/li\u003e\n\u003cli\u003ePositive data could create niche value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend’s Early Bets: High Upside, High Uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech Corporation’s Question Marks are early, high-upside bets with weak current share. CD20 and CD19 face crowded CAR-T markets, while CD22 and T-cell lymphoma are still too early to prove durable wins. The Phase I gastric cancer program is first-in-human, so only early safety and response data can reprice it.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCD20 CAR-T\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eCrowded market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCD22 CAR-T\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eDurability unproven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGastric cancer\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eFirst-in-human\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234681921801,"sku":"legn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/legn-bcg-matrix.webp?v=1785723658","url":"https:\/\/dcfanalyst.com\/products\/legn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}